David A. Siegel Annexon, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Annexon, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 37,200 shares of ANNX stock, worth $194,556. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,200

Previous 119,400 68.84%

Holding current value

$194,556

Previous $585,000 62.39%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $369,078 - $591,840	-82,200 Reduced 68.84%	37,200 $220,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $6.79 $324,750 - $509,250	-75,000 Reduced 38.58%	119,400 $585,000
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $441,688 - $855,976	109,600 Added 129.25%	194,400 $1.39 Million
Q4 2023 Feb 14, 2024	SELL	$1.63 - $4.63 $114,751 - $325,952	-70,400 Reduced 45.36%	84,800 $384,000
Q3 2023 Nov 14, 2023	SELL	$2.13 - $3.84 $202,137 - $364,416	-94,900 Reduced 37.94%	155,200 $366,000
Q2 2023 Aug 14, 2023	BUY	$2.1 - $6.37 $308,910 - $937,027	147,100 Added 142.82%	250,100 $880,000
Q1 2023 May 15, 2023	BUY	$3.74 - $7.46 $36,652 - $73,108	9,800 Added 10.52%	103,000 $396,000
Q4 2022 Feb 14, 2023	SELL	$4.56 - $6.61 $112,175 - $162,606	-24,600 Reduced 20.88%	93,200 $481,000
Q3 2022 Nov 14, 2022	SELL	$3.75 - $6.63 $143,625 - $253,929	-38,300 Reduced 24.54%	117,800 $728,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $4.06 $65,409 - $125,859	31,000 Added 24.78%	156,100 $588,000
Q1 2022 May 16, 2022	BUY	$2.73 - $11.94 $341,523 - $1.49 Million	125,100 New	125,100 $342,000

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $249M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account